Curated News
By: NewsRamp Editorial Staff
September 08, 2026
Greenland Mines Sets Q4 Biotech Spin-Off as It Sharpens Critical Minerals Focus
TLDR
- Greenland Mines gains Nasdaq compliance and a $2.05B NPV project, positioning it strongly in rare earths for investors.
- Greenland Mines completed the Sarfartoq acquisition, with S-K 1300 assessment showing 118.6% IRR, and plans biotech spin-off in Q4 2026.
- Greenland Mines' rare earth project supports a diversified supply chain, reducing dependence on China for critical materials.
- Greenland Mines' ST1 deposit could produce 34% of non-China NdPr refining, highlighting its strategic importance.
Impact - Why it Matters
This news matters because it signals a strategic shift in the critical minerals sector, which is vital for the global transition to clean energy. Greenland Mines' focus on rare earths, particularly NdPr, addresses a critical supply chain gap outside China. The Sarfartoq project's impressive economic indicators and significant production potential could help diversify the Western supply of these essential materials, reducing dependence on Chinese exports. For investors, the spin-off of the biotech division creates a pure-play critical minerals investment opportunity, while the board changes bring fresh expertise to guide the company's growth. As demand for electric vehicles and renewable energy surges, the development of projects like Sarfartoq is essential for ensuring a stable and secure supply of rare earth elements, making this news relevant to anyone concerned with energy security, technological innovation, and sustainable development.
Summary
Greenland Mines (NASDAQ: GRML) has announced a series of strategic milestones as it pivots to become a focused rare earths and critical minerals company. The company revealed plans to spin off its biotechnology division in Q4 2026, following Nasdaq's formal approval of its March 2026 transaction, which resolved prior deficiencies and brought the company into full compliance with listing requirements. This move underscores Greenland Mines' commitment to streamlining its operations and concentrating on its core mining assets.
Key among these assets is the Sarfartoq project in southwest Greenland, which the company completed acquiring on Sept. 1 after receiving government approval. An independent S-K 1300 Initial Assessment for the ST1 deposit at Sarfartoq estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. The project is expected to produce neodymium-praseodymium (NdPr) oxide, a critical component for permanent magnets used in electric vehicles and wind turbines, at levels equivalent to about 34% of current NdPr refining outside China based on 2025 consumption, during each of its nine scheduled operating years. This positions Greenland Mines as a significant potential supplier in the Western rare earths supply chain.
The company is also reshaping its board, with Riad El-Dada and Dr. Shalom Hirschman stepping down and capital markets veteran Jason Hawkins joining. Hawkins brings extensive experience in finance and capital markets, which will be invaluable as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project. These developments align with the company's vision of building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, all under its broader North Atlantic Critical Metals Corridor strategy. The full press release can be accessed at https://ibn.fm/QN1U9, and the latest updates are available in the company's newsroom at https://ibn.fm/GRML.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Greenland Mines Sets Q4 Biotech Spin-Off as It Sharpens Critical Minerals Focus
